Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00484315 · ClinicalTrials.gov registry record · Phase 3
TAXUS PERSEUS Workhorse
A Phase 3 study of Coronary Artery Disease, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,264
- Enrollment target
- 20
- Study locations
NCT00484315 is a Phase 3 study of Coronary Artery Disease that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,264 participants, roughly in line with the 1,281-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target. The trial reports 20 study locations across 9 states.
The verdict
NCT00484315, a Phase 3 study of Coronary Artery Disease, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,264 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 28 mm in length in native coronary arteries of 2.75 mm to 4.0 mm diameter.
Conditions Studied
Interventions
- DEVICE Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
- DEVICE Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
Study Locations (20)
California
- Bakersfield Memorial Hospital - Bakersfield
- Alvarado Hospital - La Jolla
- Scripps Clinic - La Jolla
- Scripps Memorial Hospital - La Jolla
- University of California, Davis Medical Center - Sacramento
- Mercy General Hospital - Sacramento
Florida
- Mediquest Research at Munroe Regional Medical Center - Ocala
- Florida Hospital - Orlando
- Sarasota Memorial Hospital - Sarasota
- Tallahassee Memorial Hospital - Tallahassee
Georgia
- Piedmont Hospital - Atlanta
- St. Joseph's Hospital of Atlanta - Atlanta
- Medical Center of Central Georgia - Macon
Alabama
- Baptist Medical Center Princeton - Birmingham
- Medical Center East - Birmingham
Colorado
- South Denver Cardiology Associates, PC - Littleton
Delaware
- Christiana Hospital - Newark
District of Columbia
- Washington Hospital Center - Washington D.C.
Hawaii
- Kaiser Foundation Hospitals - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,264 participants |
| Start Date | 2007-07 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00484315
The ClinicalTrials.gov registry entry for NCT00484315 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,264 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,281-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation is the first listed.
NCT00484315 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00484315 about?
NCT00484315 is a clinical study titled "TAXUS PERSEUS Workhorse". The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 28 mm in length in native coronary arteries...
What is the current status of trial NCT00484315?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,264 participants. The study started on 2007-07. Estimated completion is 2013-10.
What conditions does trial NCT00484315 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT00484315?
The interventions under investigation include: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation (DEVICE), Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement (DEVICE).
Who is sponsoring clinical trial NCT00484315?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00484315 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
RECRUITING · Phase 3
-
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities
RECRUITING · Phase 3
-
PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients
ACTIVE NOT RECRUITING · Phase 3
-
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.